- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Dermatologic Manifestations
Question | Discussion | References | CME Credit
Case 2: Acyclovir-Resistant Herpes Simplex Virus Infection
You answered:
 |
Acyclovir (Zovirax) 10 mg/kg IV q8h. |
|---|
This answer is incorrect. Using a very high dose of acyclovir (Zovirax) would not likely override the acyclovir resistance and thus intravenous acyclovir would not be an optimal choice.
Choose another answer:
 |
Famciclovir (Famvir) 500 mg PO tid. |
|---|---|
 |
Foscarnet (Foscavir) 40 mg/kg IV q8h. |
 |
Valacyclovir (Valtrex) 1000 mg PO tid. |
Copyright © 2004-2013 University of Washington